Effects of androgen deprivation therapy on metabolic markers and bioelectrical impedance analyze in prostate cancer patients

dc.authorid0000-0002-0176-5887
dc.authorid0000-0001-6382-1306
dc.contributor.authorÇakıcı, Mehmet Çağlar
dc.contributor.authorCan, Bulent
dc.contributor.authorKazan, Ozgur
dc.contributor.authorEfiloglu, Ozgur
dc.contributor.authorSendogan, Furkan
dc.contributor.authorUcar, Taha
dc.contributor.authorTuran, Turgay
dc.date.accessioned2025-05-10T19:48:29Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractIntroduction and Objectives: Prostate cancer (PCa) is the most widespread malignancy within men. Androgen deprivation therapy (ADT), which is the central component of advanced PCa treatment, causes side effects. The goat of this study was to examine the metabolic changes and bioelectrical impedance analysis differences in PCa patients who received ADT. Materials and methods: After age-related match-pair analysis, a total of 519 patients with PCa and control group who had benign disease were enrolled in the study. Biochemical blood parameters and TANITA measurements were recorded for all patients. Patients were categorized into three groups, ADT group (Group 1, n= 124) and non-ADT group (Group 2, n = 248), control group (Group 3, n = 147). Results: The mean age of groups was similar. Body mass index, waist circumference, body fat mass and fat ratio, which were among the TANITA parameters, were higher in group 1 (p< 0.05). Total cholesterol, high density lipoprotein, non- high density lipoprotein, triglycerids and fasting blood glucose values were also higher in group 1 (p <0.05). Myocardial infarction and metabolic syndrome rates were also higher in this group. Conclusions: While the use of ADT is manifested by an increase in fat mass and fat ratio in body composition, it negatively affects waist circumference measurements. It is associated with metabolically unfit body composition changes that predispose to diabetes mellitus and may increase cardio-vascular disease. For this reason, it is necessary to be careful about metabolic and endocrinological diseases in long-term therapy. (C) 2022 Asociacion Espanola de Andrologia, Medicina Sexual y Reproductiva. Published by Elsevier Espana, S.L.U. All rights reserved.
dc.identifier.doi10.1016/j.androl.2020.10.007
dc.identifier.endpage101
dc.identifier.issn1698-031X
dc.identifier.issue2
dc.identifier.pmid35115256
dc.identifier.scopus2-s2.0-85123856205
dc.identifier.scopusqualityQ3
dc.identifier.startpage96
dc.identifier.urihttps://doi.org/10.1016/j.androl.2020.10.007
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11716
dc.identifier.volume20
dc.identifier.wosWOS:000832999000004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Espana Slu
dc.relation.ispartofRevista Internacional De Andrologia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectAndrogen deprivation therapy
dc.subjectBioetectricat impedance analyze
dc.subjectBody composition
dc.subjectMetabolic effect
dc.subjectProstate cancer
dc.titleEffects of androgen deprivation therapy on metabolic markers and bioelectrical impedance analyze in prostate cancer patients
dc.typeArticle

Dosyalar